Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27440452 | 0.85 | RAB9A (0.47) | RAB9ALMNAMAPK1HTTTUBB1 | |
| SCHEMBL1277335 | 0.84 | CA12 (0.48) | RAB9ALMNAMAPK1HTTCA12 | |
| SCHEMBL22472 | 0.84 | CA12 (0.43) | LMNACA12CA1CA2CA7 | |
| SCHEMBL29809608 | 0.83 | CA12 (0.62) | RAB9ALMNAMAPK1HTTTUBB1 | |
| SCHEMBL370408 | 0.83 | CA12 (0.62) | RAB9ALMNAMAPK1HTTTUBB1 | |
| SCHEMBL23115 | 0.81 | CA2 (0.67) | MAPK1HTTTUBB1CA12CA1 | |
| SCHEMBL8832273 | 0.80 | BACE1 (0.34) | KDM1AMEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL2575428 | 0.79 | KCNQ3 (0.36) | MEN1ALDH1A1KMT2AMAPTL3MBTL1 | |
| SCHEMBL177773 | 0.79 | KDM1A (0.46) | HTTTUBB1KDM1AMAPTL3MBTL1 | |
| SCHEMBL23744 | 0.78 | CA12 (0.45) | LMNATUBB1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117062813-B | Polycyclic compound and application thereof | 四川汇宇制药股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20250276509-A1 | ORGANIC LIGHT EMITTING DIODE DISPLAY | SAMSUNG DISPLAY CO LTD (KR) | 2025-09-04 | — | — | US | disclosed |
| EP-3521366-B1 | CURABLE MODIFIED PETROLEUM RESIN, AND PREPARATION METHOD AND USE THEREOF | KOLON INC (KR) | 2025-07-30 | — | — | EP | disclosed |
| WO-2025149586-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF FATTY LIVER DISEASE | SCANDIEDGE THERAPEUTICS AB (SE) | 2025-07-17 | — | — | WO | disclosed |
| EP-4585216-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF FATTY LIVER DISEASE | ScandiEdge Therapeutics AB (SE) | 2025-07-16 | — | — | EP | disclosed |
| CN-120129677-A | Compounds and their use for the treatment of heme lesions | 百时美施贵宝公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-120077035-A | As CX32,4, 6-Trisubstituted 1,3, 5-triazines as modulators of CR1 | 阿斯利康(瑞典)有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-12310224-B2 | Organic light emitting diode display | SAMSUNG DISPLAY CO., LTD. (KR) | 2025-05-20 | — | — | US | disclosed |
| CN-118302418-B | Aromatic heterocyclic compound and application thereof | 中国科学院上海药物研究所 | 2025-05-02 | — | — | CN | disclosed |
| CN-117843641-B | NSD3 inhibitor and preparation method and application thereof | 和径医药科技（上海）有限公司 | 2025-04-25 | — | — | CN | disclosed |
| EP-1453782-A2 | SUBSTITUTED PHENYL NAPHTHALENES AS ESTROGENIC AGENTS | Wyeth (US) | 2004-09-08 | — | — | EP | disclosed |
| EP-1412327-A2 | INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE | LG Biomedical Institute (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030208067-A1 | Inhibitors of protein kinase for the treatment of disease | LG BIOMEDICAL INSTITUTE | 2003-11-06 | — | — | US | disclosed |
| US-20030187007-A1 | Inhibitors of protein kinase for the treatment of disease | LG BIOMEDICAL INSTITUTE | 2003-10-02 | — | — | US | disclosed |
| US-20030181519-A1 | Substituted phenyl naphthalenes as estrogenic agents | WYETH | 2003-09-25 | — | — | US | disclosed |
| WO-2003051805-A2 | SUBSTITUTED PHENYL NAPHTHALENES AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-26 | — | — | WO | disclosed |
| WO-2002096867-A2 | INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE | LG BIOMEDICAL INSTITUTE (US) | 2002-12-05 | — | — | WO | disclosed |
| EP-0637624-B1 | Antiferroelectric liquid crystal compound | SHOWA SHELL SEKIYU (JP) | 1996-09-25 | — | — | EP | disclosed |
| US-5417885-A | Antiferroelectric liquid crystal compound | SHOWA SHELL SEKIYU KABUSHIKI KAISHA (JP) | 1995-05-23 | — | — | US | disclosed |
| EP-0637624-A1 | Antiferroelectric liquid crystal compound | Showa Shell Sekiyu Kabushiki Kaisha (JP) | 1995-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181519-A1 | Substituted phenyl naphthalenes as estrogenic agents | ESR2, ESR1, ESRRA | RAB9A 1085/4885LMNA 2963/4885MAPK1 675/4885 |
| US-20030208067-A1 | Inhibitors of protein kinase for the treatment of disease | MAP3K20, MAP3K1, MAP3K2 | RAB9A 3067/4885LMNA 1364/4885MAPK1 47/4885 |
| US-20030187007-A1 | Inhibitors of protein kinase for the treatment of disease | MAP3K20, MAP3K1, MAP3K2 | RAB9A 3067/4885LMNA 1364/4885MAPK1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.